NuCana plc ( NCNA) Stock. Should you Buy or Sell? $ 1.58
0.05 (3.07 %)
NuCana plc AnalysisUpdated on 10-09-2022
|Volume Avg.||$314 thousand|
|Market Cap||$82.47 M|
|52 Week Range||$0.517 - $3.32|
NuCana plc opened the day at $1.58 which is +'3.07 % on yesterday's close. NuCana plc has a 52 week high of $3.32 and 52 week low of $0.517, which is a difference of $2.803. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $82.47 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy NuCana plc for $82.47 M, it would take 15 years to get your money back. NuCana plc are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
NuCana plc Stock Forecast - Is NuCana plc a Buy or Sell?
|DCF Score||Strong Buy|
Growth and Value
|Net Profit Margin||0.000|
Valuing NuCana plc
|Price Book Value Ratio||1.074||Price To Book Ratio||1.074|
|Price To Sales Ratio||0.000||Price Earnings Ratio||-1.772|
How liquid is NuCana plc
|Debt Ratio||0.159||Debt Equity Ratio||0.189|
|Long Term Debt To Capitalization||0.002||Total Debt To Capitalization||0.004|
Latest news about NuCana plc
NuCana trades at a bit more than half its cash position as a result of a March 2022 sell-off, caused by the trial discontinuation of the furthest-advanced drug candidate. The company's current drug candidates, NUC-3373 and NUC-7738, show remarkable results across different solid tumors, either substantially improving chemotherapy or creating novel treatment.
Regional Court of Dusseldorf has ruled in favor of NuCana plc (NASDAQ: NCNA), stating that Gilead Sciences Ireland UC and Gilead Sciences GmbH infringed NuCana's composition of matter claims in European Patent 2955190 through their sales of Sovaldi, Harvoni, Vosevi and.
EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in two upcoming virtual investor conferences.
Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.
NuCana: Preparing For A Critical 2022
About NuCana plc
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.